This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer
by Zacks Equity Research
AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.
AZNPositive Net Change NVSPositive Net Change PFENegative Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
by Ahan Chakraborty
Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
by Kanishka Das
PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
PGENPositive Net Change MRKPositive Net Change INONegative Net Change
biotechs
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
by Ekta Bagri
Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
LQDAPositive Net Change UTHRNegative Net Change INSMPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.
BMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
by Zacks Equity Research
Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
LQDAPositive Net Change UTHRNegative Net Change INSMPositive Net Change
biotechnology biotechs medical pharmaceuticals
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
by Zacks Equity Research
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
AZNPositive Net Change AMGNPositive Net Change RHHBYPositive Net Change JAZZPositive Net Change
biotechs medical pharmaceuticals
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
by Sundeep Ganoria
ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.
ABBVNegative Net Change SNYPositive Net Change JNJPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
by Kanishka Das
Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
PGENPositive Net Change MRKPositive Net Change INONegative Net Change
biotechs
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
by Zacks Equity Research
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
NVSPositive Net Change RGENNegative Net Change ANIKNegative Net Change IONSNegative Net Change
biotechnology biotechs medical pharmaceuticals